Abstract The lower sensitivity of the inflamed nasal mucosa to glucocorticoids might be related to an increased expression of the glucocorticoid receptor (GR) beta isoform.We investigated GRa and GRb mRNA expression in epithelial cells from nasal mucosa and nasal polyps.GRa mRNA was at least1000 times more expressed than GRb mRNA in both tissues.GRb expression (mean7SEM of 10 3 cDNA copies/mg of total RNA) was higher in nasal polyps (1.1570.19; n=27; Po0.01) than in nasal mucosa (0.6270.10; n=32). Nasal polyps with43% of inflammatory cells had higher GRb levels (1.4070.29; n=16) than both nasal mucosa (Po0.01) and polyps with r3% of inflammatory cells (0.8070.18; n=11; Po0.05).No difference in GRbexpression was found between nasalmucosa and polyps with r 3% of inflammatory cells. GRb expression correlated with the inflammatory cell number, especially with mast cells (r=0.50, Po0.0001). There was no difference in GRa mRNA expression between nasal mucosa and nasal polyps. In summary,GRa is far more expressed than GRbin bothtissues.The increased expression of GRb may be related to the presence of inflammatory cells.
INTRODUCTION
Nasal polyps are evaginations from the sinus mucosa and the middle turbinate that are in¢ltrated with in£amma-tory cells, mainly eosinophils and mast cells (1, 2) . Glucocorticoids are the most frequently administered drugs with a proven e¡ect on reducing polyp size and in£am-mation. However, not all patients with nasal polyposis respond to corticosteroid treatment, some of them require surgery despite glucocorticoid maintenance therapy (1) . These observations suggest that nasal polyps consist of a tissue relatively resistant to glucocorticoids, but the underlying mechanisms leading to this poor response are as yet unclear.
We previously reported that some cytokines secreted by nasal mucosa and nasal polyp epithelial cells enhance eosinophil survival (2) . We also found that glucocorticoids inhibit the survival-promoting e¡ect of the epithelial cell secretions, but this e¡ect was less potent in epithelial secretions from nasal polyps than in those from healthy nasal mucosa (2) .This ¢nding suggested a relative resistance of nasal polyp epithelial cells to the e¡ect of glucocorticoids.
Suboptimal response to glucocorticoids has been described in a number of diseases but it has been mainly investigated in bronchial asthma. The asthmatic patients who are at the lower end of the glucocorticoid response range are considered to be glucocorticoid resistant (3) . The rationale of our study is based on the fact that nasal and bronchial diseases should be part of the same pathogenic process and that the mechanisms involving glucocorticoid dependence/resistance in asthma may also account for nasal polyposis.
The biological action of glucocorticoids is mediated through activation of intracellular glucocorticoid receptors (GRs) (4) . Two human isoforms of GR have been identi¢ed, GRa and GRb, which originate from the same gene by alternative splicing of the GR primary transcript (5) .Upon hormone binding,GRa is phosphorylated, dissociated from heat shock proteins and translocated to the cell nucleus. As a homodimer, GRa binds to speci¢c sequences within the promoter region of target genes, leading to an enhancement or a repression of their transcription. However, most of the antiin£ammatory e¡ects of glucocorticoids are mediated through protein^protein interactions between GR and transcription factors, such as AP-1 and NF-kB (6) . The GRb isoform di¡ers from GRa in its carboxy terminus, where the last 50 amino acids of GRa are replaced by a non-homologous 15 amino acid sequence. GRb neither binds glucocorticoids nor trans-activates target genes (5, 7) . Transfection studies have revealed the ability of GRb to act as a dominant negative inhibitor of GRa activity (5, 8) through a mechanism that involves the formation of transcriptionally impaired GRa-GRb heterodimers (8) . However, other studies have challenged this concept (7, 9, 10) .
There may be several mechanisms accounting for the resistance to the antiin£ammatory e¡ects of glucocorticoids. Certain proin£ammatory cytokines may induce activation of the transcription factor AP-1, which would block the activated GRa, thereby leading to an impaired suppression of the in£ammatory response (11) . Another suggested mechanism is the cytokinedriven reduction of the GRa binding a⁄nity for glucocorticoids (12) . An overexpression of GRb may also be involved in glucocorticoid-resistant diseases. Thus, increased expression of GRb has been reported in patients with glucocorticoid-insensitive asthma (13^15), ulcerative colitis (16) , nasal polyps (17) and in one patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia (18) . Downregulation of GRa levels after treatment with glucocorticoids (19^21) has also been postulated to be one of the possible explanations for the secondary glucocorticoid resistance phenomenon (6) .
We hypothesized that the lower sensitivity of the nasal polyp epithelia to glucocorticoids might be due, at least in part, to an increased expression of GRb in epithelial cells. This study was designed to test this hypothesis.
SUBJECTS AND METHODS

Subjects
Human nasal mucosa was obtained from 32 healthy subjects (20 males) aged 30.372.4 years, undergoing nasal corrective surgery for turbinate hypertrophy or septal dismorphy. None of the subjects were treated with corticosteroids. The skin-prick test for common allergens was positive in ¢ve subjects (16%) and negative in 27 (84%).
Nasal polyps were obtained from 27 patients (19 males) aged 4772.6 years, undergoing nasal polypectomy. At the time when polypectomy was carried out, eight patients (30%) were receiving intranasal corticosteroids (£uticasone or budesonide, 200^400 mg/day), one (4%) was receiving oral prednisone (40 mg/day), and six (22%) were receiving both intranasal (budesonide or £uticasone, 400 mg/day) and oral corticosteroids (prednisone or de£azacort, 20^40 mg/day). The remaining 12 patients (44%) had not received steroid treatment for at least1month prior to surgery.Twelve subjects (44%) had asthma, half of these were aspirin-intolerant. The skinprick test was positive in ¢ve patients (18%), negative in 16 (59%), and it could not be determined in the remaining six patients (22%).The study was approved by the Ethics Committee of our Institution.
Preparation of epithelial cell extracts
Freshly obtained nasal mucosa and nasal polyp specimens were digested with protease and nasal epithelial cell extracts were isolated as previously reported (2) . Cell viability was assessed by trypan blue dye exclusion in a haemocytometer. Cell population was histologically characterized using smears obtained by cytocentrifugation (500 rpm,10 min) and stained with May^GrˇnwaldĜ iemsa (MGG). After tissue protease digestion, cell viability was 9470.8% for nasal mucosa and 9570.9% for nasal polyps. Compared with healthy mucosa, nasal polyps provided a signi¢cantly larger percentage of eosinophils, neutrophils and metachromatic cells (Table 1) . Previous studies have shown that most of the metachromatic cells identi¢ed in nasal polyps through histochemical staining methods correspond to mast cells, as identi¢ed using immunohistochemical staining protocols (22) . The percentage of each in£ammatory cell type was not signi¢cantly di¡erent in asthmatics with respect to non-asthmatics. However, there was a tendency for a higher number of eosinophils in patients with aspirin-intolerant asthma (12.372.5%; n=6) compared to aspirintolerant asthmatics (6.471.6%; n=21; P=0.087). There was no di¡erence in the individual in£ammatory cell count between the glucocorticoid-treated polyps and the non-treated ones. Nasal polyps with a positive skinprick test provided a higher number of neutrophils (471%; n=5) than those with a negative skin-prick test (1.870.3%; n=16; Po0.05). There was no di¡erence between these two groups of patients with respect to the cell counts of all other in£ammatory cell types. Nasal polyp cell extracts, which had a higher percentage of in£ammatory cells than those of nasal mucosa, were processed for panning with an ICAM-3 antibody that e⁄ciently recognizes the ICAM-3 antigen of leucocytes and mast cells (23) . Thus, cells were incubated for 1h at 41C on a Petri dish preabsorbed with the ICAM-3 antibody and were subsequently washed, centrifuged and characterized by MGG staining. After cell panning the percentage of in£ammatory cells was reduced to 6.071.1%, but it was still signi¢cantly higher than in nasal mucosa (2.570.3%) ( Table 1) . To normalize the in£ammatory cell content of polyps to that of nasal mucosa, polyps were classi¢ed into two groups: those which had a percentage of in£ammatory cells similar to that of nasal mucosa, i.e. r3%, and those with an in£am-matory cell content 43% (Table 1) . Finally, 3^10 Â10 6 of total cells from either nasal mucosa or nasal polyp epithelial cell extracts were pelleted and frozen at À801C until RNA analysis.
Reverse transcriptionFcompetitive PCR
Total RNA from nasal mucosa and nasal polyp epithelial cells was isolated using a rapid extraction method (TRIReagent) and reverse transcribed to complementary DNA (cDNA), as previously described (20) . GRa and GRb cDNAs were analyzed by competitive PCR, which is an accurate and sensitive method to quantify gene expression (24, 25) . This technique is based on the coampli¢cation of the target cDNA and known amounts of an exogenous DNA, called competitor or internal standard, in the same test tube (20) . Since the initial amount of internal standard was known, the initial amount of target cDNA was determined.
GRa and GRb PCR reactions were performed before reaching the plateau phase. Primers were designed to span introns, so that any genomic DNA product would be distinguished from the target cDNA by size di¡erence. GRa and GRb cDNAs were ampli¢ed using speci¢c antisense primers that shared the same sense primer, whose sequences were as follows:
(GRa antisense), and 5 0 -ATTATCCAGCACTTCATAGA-CACAAAT-3 0 (GRb antisense), corresponding to nucleotide start positions 1869, 2692, and 2870, respectively. The PCR reaction and cycling conditions have been extensively described elsewhere (20) . Both, GRa-and GRb-speci¢c primers ampli¢ed their respective target cDNA and competitor with the same e⁄-ciency. In addition, this competitive PCR assay was sensitive enough to detect two-fold di¡erences in GR expression.
To ensure that the RNA was e¡ectively reverse transcribed to cDNA, the PCR for the housekeeping gene glyceraldehyde-3-phosphate dehydrogenase was routinely performed for each sample.
Statistical data analysis
The expression of GRa or GRb mRNA is expressed as the arithmetic mean7standard error of the mean (SEM) of10 3 copies of GRa or GRb cDNA per mg of total RNA. Statistical comparisons were performed using analysis of variance (ANOVA) with the Dunnett t-test. Po0.05 was regarded as statistically signi¢cant.
RESULTS
The expression of GRa mRNA was much higher than GRb mRNA expression in all specimens. Thus, the GRa/ GRb ratio was 32247402 for nasal mucosa (n=32) and 17227289 for the nasal polyp epithelial cell extracts (n=27; Po0.01).
However, there was a higher expression of GRb mRNA ( Â10 3 cDNA copies/mg of total RNA) in the epithelial cell extracts from nasal polyps (1.1570.19; Po0.01) than in those from nasal mucosa (0.6270.10). After classifying the nasal polyps into two groups, according to their in£ammatory cell content, we found an even more increased expression of GRb mRNA in those polyps that had more than 3% of in£ammatory cells (1.4070.29; GRa/GRb ratio=13727390; n=16), when compared to both nasal mucosa (Po0.01) and polyps with r3% of in£ammatory cells (0.8070.18; GRa/GRb ratio=22307395; n=11; Po0.05) (Fig. 1) . However, no statistical di¡erence in GRb mRNA expression was found between nasal mucosa and nasal polyps with r3% of in£ammatory cells. In addition, a linear correlation was found between GRb mRNA expression and the percentage of in£ammatory cells in all studied specimens (r=0.38; n=59; Po0.01) (Fig. 2) . More speci¢cally, there was strong correlation between GRb expression and the number of metachromatic cells in all specimens (r=0.50; n=59; Po0.0001) (Fig. 2) , as well as in all nasal polyps (r=0.49; n=27; Po0.01) and nasal polyps with more than 3% of in£ammatory cells (r=0.60; n=16; Po0.05). No correlation was found between GRb mRNA expression and other in£ammatory cells (neutrophils, eosinophils and lymphocytes) (Fig. 2) .
In contrast, no di¡erences in GRa mRNA expression were found between nasal mucosa (16907240; n=32) and all nasal polyps (13707190; n=27; NS), nor between nasal mucosa and polyps with either less (16707410; n=11; NS) or more (11707160; n=16; NS) than 3% of in£ammatory cells (Fig. 1) . There was no correlation between GRa mRNA expression and the in£ammatory cell count.
No di¡erences in the expression of GRa or GRb mRNA were found between asthmatics (GRa= 15607310; GRb=1.2970.26; n=12) and non-asthmatic subjects (GRa=12307250; GRb=1.0370.28; n=15), nor between aspirin-tolerant (GRa=14707240; GRb= 1.1370.23; n=21) and aspirin-intolerant asthmatics (GRa=10507200; GRb=1.2070.35; n=6). No signi¢cant di¡erences in either GRa or GRb mRNA expression were found between glucocorticoid-treated polyps (GRa=11907160; GRb=1.2470.28; n=15) and non-treated polyps (GRa=16007390; GRb=1.0370.26; n=12). In nasal mucosa specimens, no di¡erences in the expression of GRa or GRb were found between atopic (GRa= 18007730; GRb=0.6370.18; n=5) and non-atopic subjects (GRa=16607260; GRb=0.6270.12; n=27). Similarly, the expression of both GR isoforms in nasal polyps was similar between atopic (GRa=12107540; GRb= 0.8570.40; n=5) and non-atopic patients (GRa=15307 270; GRb=1.3570.25; n=16).
DISCUSSION
It is well established that some patients with nasal polyps fail to respond to glucocorticoid therapy (1) .On the basis of our previous studies suggesting a relative resistance of FIG. 1. Expression of GRa and GRb mRNA in nasal mucosa and nasal polyp epithelial cell extracts with either r3% or 43% of in£ammatory cells.Total cellular RNA from nasal mucosa and nasal polyp epithelial cell extracts was isolated and reverse transcribed to cDNA.GRa and GRb cDNAs were ampli¢ed by competitive PCR using GRa-and GRb-speci¢c primers.Four serial dilutions of the competitors (internal standard, GRa-S or GRb-S) were added to a constant amount of target cDNA. After ampli¢cation, the PCR products were resolved by agarose gel electrophoresis and ethidum bromide staining.The relative amounts of target and GR-S products, which di¡eredin size, were analyzed and comparedin each sample bydensitometric analysis.Because the amountof GR-S added to each PCR reactionwas known, the absolute initial amountoftargetcould be determined.Insets show representative gels ofthe GRa and GRb PCR products, with four increasing dilutions of GRa-S (1091bp) or GRb-S (1118 bp), which compete with a constant amount of the target cDNA (GRa, 824 bp; GRb,1002 bp).
nasal polyp epithelial cells to the antiin£ammatory e¡ect of glucocorticoids (2), we hypothesized that nasal polyp epithelial cells might mediate part of this resistance through overexpression of the GRb isoform. The aim of this study was to evaluate the expression of GRa and GRb isoforms in epithelial cell extracts from nasal mucosa and nasal polyps.The main ¢ndings of our study were: (1) GRa mRNA expression was more than 1000 times higher than that of GRb in both nasal mucosa and polyps, (2) GRb expression was higher in nasal polyps than in nasal mucosa, (3) the increased expression of GRb in nasal polyps correlated with the in£ammatory cell number.
The expression of GRb mRNA was found to be much less abundant than that of GRa in both nasal mucosa (GRa/GRb ratio=32247402) and nasal polyps (GRa/ GRb ratio=17227289). These ¢ndings are in line with RT-PCR and Northern blot analysis performed on whole human tissues and cell lines (5,16,20,26^28 ). Oakley and coworkers (5), using external standards to quantify the GR transcripts, reported about 200^500 times more GRa mRNA than GRb mRNA in two adult tissues and two human cell lines. Using a semi-quantitative RT-PCR approach, Honda and coworkers (16) detected GRb mRNA in only 10% of the PBMCs from healthy subjects. The authors detected GRb mRNA in 83% of the PBMCs from patients with glucocorticoid-resistant ulcerative colitis, but its concentration was still 605 times lower than the GRa message. Cell-type-speci¢c di¡erences or di¡erences in the RT-PCR technique used may account for the variability in the GRa/GRb ratio reported among di¡erent investigators. Other researchers have even required the use of nested PCR to detect the GRb transcript (27) .
At the protein level, Western blotting studies have revealed little (7, 16, 29) or any GRb (20, 27) reported expression of GRb protein in in£ammatory cells (13^15,17,30^32).Thus,GRb has been detected in human neutrophils from healthy subjects (31) , in airway Tcells (14, 15) and macrophages (15) from glucocorticoid-insensitive asthmatics, and in in£ammatory cells from patients with nasal polyposis (17) . The expression of GRb in cell types of non-in£ammatory origin has been hardly investigated. Oakley and coworkers (29) detected GRb only in a few cell types within the whole tissue, namely, the epithelial cells lining the terminal bronchiole of the lung, forming the outer layer of Hassall's corpuscle in the thymus, and lining the bile duct in the liver.
An increased expression of GRb mRNA was found in epithelial cell extracts from nasal polyps compared to nasal mucosa, which was more evident in those polyp samples containing more than 3% of in£ammatory cells. The higher expression of GRb in nasal polyps apparently accounts for the in£ammatory cells that remained after panning, for a correlation was found between GRb expression and the number of in£ammatory cells, especially mast cells, present in the epithelial cell extracts. We are tempted to speculate that if we had not removed the in£ammatory cell content from nasal polyps, we would probably have found a more marked di¡erence in the expression of GRb mRNA in nasal polyps with respect to nasal mucosa. Indeed, Hamilos and coworkers (17) have recently reported that GRb expression in nasal polyps is con¢ned to in£ammatory cells, particularly T lymphocytes, eosinophils, and macrophages.The authors also reported increased number of GRb-positive in£am-matory cells in nasal polyps compared to control middle turbinates. Our results showing increased GRb expression in epithelial cell extracts from nasal polyps are not in contradiction with those of Hamilos (17) . Our ¢ndings reveal that epithelial cells, as opposed to in£ammatory cells, from either nasal mucosa or polyps do not signi¢-cantly express GRb, and further reinforce the concept that the expression of GRb is mainly restricted to in£am-matory cells. Contradicting our hypothesis, the relative resistance of nasal polyp epithelial cells to the antiin£am-matory e¡ect of glucocorticoids (2) does not account for an overexpression of GRb in these cells.
The relationship between insensitivity to glucocorticoid treatment and increased expression of GRb has also been reported in asthma (13^15,30), ulcerative colitis (16) , as well as in chronic lymphocytic leukemia associated with systemic glucocorticoid resistance (18) . Increased GRb has also been found in animal models of systemic glucocorticoid resistance (33) . However, other investigators have not observed any correlation between GRb expression and glucocorticoid insensitivity. For instance,Gagliardo and coworkers (27) were unable to ¢nd increased GRb expression in PBMCs from patients with glucocorticoid-dependent asthma. Similarly, no signi¢-cant di¡erences in GRb expression were observed in both pituitary and ectopic ACTH-secreting tumors (26) . In addition, the possible physiological role of GRb is still a matter of debate (33, 34) . Cotransfection studies have shown that when GRb is more abundant than GRa, GRb acts as a dominant negative inhibitor of GRa activity (5) through a mechanism which mostly involves the formation of transcriptionally impaired GRa^GRb heterodimers (8) . However, other researches found no evidence of a speci¢c dominant negative e¡ect of GRb on GRa activity (7, 9, 10) . Although certain cell types are known to contain GRb, further studies analyzing the GRa/GRb ratio are needed. In addition, the possible contribution of a few cells overexpressing GRb to the disease condition is as yet unknown.
In summary, we report that GRa mRNA expression is far more abundant than the expression of GRb in both nasal mucosa and nasal polyp epithelial cells. The increased expression of GRb mRNA in nasal polyps correlates with the number of in£ammatory cells present in the nasal polyp extracts.Our results suggest that epithelial cells from either nasal mucosa or nasal polyps are not a primary target for GRb expression.
